SILK
Silk Road Medical, Inc
Set alert
52-week range unavailable
- Open
- 27.49
- Prev close
- 27.49
- Mkt cap
- 1.12B
- Vol
- 2.31M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 27.49
- High
- 27.50
- Forward P/E
- -20.98
- Beta
- 1.54
- Short ratio
- 2.48
- Inst. own
- 97.46%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 27.17
- 200-d avg
- 21.00
- 1y target
- 20.75
Key statistics
- Market cap
- 1.12B
- Enterprise value
- 1.03B
- Trailing P/E
- 0.00
- Forward P/E
- -20.98
- PEG ratio
- -11.77
- Price / sales
- 5.83
- Price / book
- 7.22
- EPS (TTM)
- -1.45
- Beta
- 1.54
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -29.53%
- Revenue (TTM)
- 191.43M
- Revenue growth
- 13.10%
- Free cash flow
- -15.35M
- Total cash
- 171.98M
- Total debt
- 84.47M
- Return on equity
- -36.45%
- Shares outstanding
- 40.63M
- Short % of float
- 7.87%
- 50-day average
- 27.17
- 200-day average
- 21.00
Analyst view
Consensus: hold
- Target (low)
- 8.00
- Target (mean)
- 20.75
- Target (high)
- 27.50
- Strong buy0
- Buy0
- Hold0
- Sell0
- Strong sell1
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.35.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 7, 2024 | Jun 1, 2024 | -0.38 | — | — | — |
| Apr 30, 2024 | Mar 1, 2024 | -0.40 | — | — | — |
| Feb 28, 2024 | Dec 1, 2023 | -0.40 | — | — | — |
| Nov 8, 2023 | Sep 1, 2023 | -0.36 | — | — | — |
| Aug 1, 2023 | Jun 1, 2023 | -0.39 | — | — | — |
| May 9, 2023 | Mar 1, 2023 | -0.39 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 10, 2023 | Piper Sandler | main | Neutral | Neutral |
| Oct 10, 2023 | CL King | down | Buy | Neutral |
| Oct 10, 2023 | Citigroup | down | Buy | Sell |
| Oct 10, 2023 | B. Riley Securities | down | Buy | Neutral |
| Oct 10, 2023 | Stifel | down | Buy | Hold |
| Sep 20, 2023 | Argus Research | down | Buy | Hold |
About Silk Road Medical, Inc
Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California. As of September 17, 2024, Silk Road Medical, Inc operates as a subsidiary of Boston Scientific Corporation.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- silkroadmed.com
News
- Boston Scientific Announces Results for Third Quarter 2024
- Boston Scientific Closes Acquisition of Silk Road Medical, Inc.
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BALY and SILK on Behalf of Shareholders
- SILK INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Merger and Looming Vote on September 5, 2024, of Silk Road Medical, Inc.
- SILK INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Merger and Looming Vote on September 5, 2024, of Silk Road Medical, Inc.
- SILK Alert: Monsey Firm of Wohl & Fruchter Renews Investigation of the Proposed Sale of Silk Road Medical to Boston Scientific
- Silk Road Medical (SILK) Reports Q2 Loss, Tops Revenue Estimates
- Silk Road Medical Celebrates Milestone of 100,000 Transcarotid Artery Revascularization (TCAR) Procedures
- SILK INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Merger of Silk Road Medical, Inc.
- STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Silk Road Medical, Inc. – SILK
Your note
Sign in to keep a note on SILK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERSON RICK D | Director | Stock Award(Grant) | Jun 17, 2024 | 11,966 |
| BALLINGER KEVIN J | Director | Stock Award(Grant) | Jun 17, 2024 | 23,666 |
| CARINO TANISHA | Director | Stock Award(Grant) | Jun 17, 2024 | 11,396 |
| CHOU TONY M | Director | Stock Award(Grant) | Jun 17, 2024 | 85,251 |
| DAVIS ANDREW S | Officer | Sale | Jul 2, 2024 | 289,707 |
| KLEMZ KEVIN M | Officer | Sale | Aug 18, 2024 | 162,926 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wasatch Advisors LP | 13.51% | 5,246,961 | 170.47M | Jun 29, 2023 |
| Vanguard Group Inc | 9.21% | 3,576,239 | 116.19M | Jun 29, 2023 |
| Blackrock Inc. | 7.64% | 2,965,739 | 96.36M | Jun 29, 2023 |
| Capital World Investors | 7.64% | 2,966,730 | 96.39M | Jun 29, 2023 |
| Alliancebernstein L.P. | 6.42% | 2,493,003 | 81.00M | Jun 29, 2023 |
| ClearBridge Investments, LLC | 4.47% | 1,736,607 | 56.42M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Smallcap World Fund | 7.64% | 2,966,730 | 96.39M | Jun 29, 2023 |
| Legg Mason Clearbridge Small Cap Growth Fd | 3.48% | 1,349,704 | 30.83M | Jul 30, 2023 |
| Vanguard Total Stock Market Index Fund | 2.88% | 1,118,088 | 36.33M | Jun 29, 2023 |
| Wasatch Ultra Growth Fund | 2.52% | 977,595 | 31.76M | Jun 29, 2023 |
| Vanguard Small-Cap Index Fund | 2.45% | 949,918 | 30.86M | Jun 29, 2023 |
| iShares Russell 2000 ETF | 2.26% | 878,220 | 16.97M | Aug 30, 2023 |